[{"from": "human", "value": "Please give me some details about this molecule. [C][C@H1][C][O][C@H1][N][Ring1][Branch1][C][=Branch1][C][=O][C][=C][Branch2][Ring2][Ring1][C][=Branch1][C][=O][C][=Branch1][Branch2][=C][N][Ring1][#Branch1][C][Ring1][N][C][=Branch1][C][=O][N][C][C][=C][Branch1][#Branch2][C][=C][Branch1][Branch1][C][=C][Ring1][=Branch1][F][F][O]"}, {"from": "gpt", "value": "The molecule is an HIV-1 integrase inhibitor that is prescribed with the non-nucleoside reverse transcriptase inhibitor, [rilpivirine]. Early research into cabotegravir showed it had lower oral bioavailability than [dolutegravir], which resulted in the development of long acting monthly intramuscular injection formulation for cabotegravir.  Cabotegravir was granted FDA approval on 21 January 2021 in combination with rilpivirine to treat HIV-1 infection in virologically suppressed individuals. While previously administered once monthly only, this combination product was granted FDA approval for dosing every two months on February 01, 2022 and without the need for an oral lead-in period prior."}]